BOSTON — Outcomes4Me Inc., a digital health company transforming cancer care through its AI-driven patient platform, announced it has secured $21 million in new funding to fuel innovation and support international expansion. The company, known for its direct-to-patient platform that offers real-time, personalized cancer care guidance, now brings its total capital raised to $38 million.
The latest investment round was led by new investor Salica Investments, based in London, and included continued support from existing backers such as Labcorp Venture Fund, Forecast Labs, Northpond Ventures, Sierra Ventures, Asset Management Ventures, IRA Capital, and Merstal LTD.
Founder and CEO Dr. Maya R. Said said the funding will accelerate Outcomes4Me’s mission to deliver intelligent, personalized treatment recommendations to cancer patients worldwide. “AI will reshape cancer care, and this investment accelerates our ability to deliver personalized treatments and improved outcomes to patients at scale,” said Said. She added that more than 280,000 patients are already using the platform, which equips them with real-time, actionable insights throughout their care journey.
Outcomes4Me’s platform integrates clinical guidelines, genomic insights, medication and symptom tracking, clinical trial matching, and patient peer support into a single user-friendly interface. The system is designed to personalize cancer treatment through advanced AI algorithms, making it easier for patients and physicians to navigate care decisions.
According to Amy Summy, Executive Vice President and Chief Marketing Officer at Labcorp, Outcomes4Me is at the forefront of digital oncology. She noted the platform’s ability to scale in a healthcare landscape increasingly demanding smarter, individualized solutions.
Since launching commercially in 2022, Outcomes4Me has achieved rapid revenue growth by partnering with life sciences companies to help connect patients with appropriate therapies and actions. Seven of the top ten global cancer pharmaceutical companies are currently among its customers, underscoring its growing influence in the oncology space.
The company has also earned significant industry recognition, receiving more than 15 awards over the past three years. It was recently ranked #12 on the Inc. Regionals Northeast 2025 list, rising from #70 the previous year, and CEO Maya R. Said was named a finalist in the 2025 EY Entrepreneur of the Year program for New England. A peer-reviewed study published in Current Oncology found Outcomes4Me to be the highest quality application among over 3,000 cancer-related mobile health apps globally.
Looking ahead, the company plans to deepen its AI capabilities, broaden its presence across more cancer types and international markets, and expand its partnerships with healthcare systems and life sciences firms. Outcomes4Me also aims to advance real-world data insights and outcomes-based evidence generation, helping to shape future standards in cancer treatment and care delivery on a global scale.
